AlphAIAlphAI — Financial news for AI agents
investing.comNOV 42 min read$HRMY

Harmony Biosciences reports Q3 revenue of $269M, reaffirms guidance

Harmony Biosciences (HRMY) reported Q3 revenue of $269M, up 12% YoY, and reaffirmed full-year guidance of $1.0B-$1.04B. Net income was $48.2M, down from $50.9M YoY. The company announced leadership changes and positive early data for BP-205. Cash reserves were $1.05B as of Q3 2026.

Original reporting
investing.com
Published Nov 4, 2026, 12:36 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 12:52 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$HRMY
Neutral
high confidence
Mentioned
$HRMY
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$HRMYNeutralMed
01

Why it matters

Earnings release provides fresh financial metrics and clinical progress, offering a basis for short‑term price moves and longer‑term valuation adjustments.

02

Market read

The report delivers new earnings data and pipeline updates that can influence HRMY's stock and related biotech peers.

03

What to watch

Increased royalty costs and modest net income decline could pressure margins if not offset by future volume growth

Relevance 8/10Novelty 8/10Timing: today

Background

Harmony Biosciences reported Q3 results, highlighted WAKIX sales, and disclosed early data on its pipeline candidate BP-205.

Company-level read

Ticker impact

$HRMYNeutralHigh confidence
Context

Q3 earnings released with $269M revenue, reaffirmed $1.0‑1.04B full-year guidance and new Phase 1b data for BP-205.

Expected impact

likely modest upward pressure as market prices in stable guidance and positive trial update

Evidence & confidence

Revenue up 12% YoY and guidance unchanged suggest no surprise downside, while the new clinical data may attract biotech interest.

Market effects

Sector

strengthens outlook for narcolepsy therapeutics and may lift peer biotech stocks in sleep‑disorder space

Regional

U.S. biotech sector may see slight gain in pre‑market trading

Global

limited to investors tracking specialty pharma earnings

Counterpoint

What could challenge this read

Guidance reaffirmation may be seen as cautious; investors could wait for Phase 2 data before adding exposure

Key entities

  • company
    Harmony Biosciences Holdings, Inc.

    NASDAQ‑listed biotech focused on narcolepsy treatments

  • person
    Peter Anastasiou

    Incoming CEO effective Jan 1 2027

Read at source← All news

StoryHarmony Biosciences posts Q3 revenue growth but EPS miss, shares slide

Also covered by

2 outlets

Related articles

NOV 4
$HRMYMed

Harmony Biosciences 3Q 2026: Revenue $268.92M, Net income $48.2M, EPS $0.81— 10-Q Summary

Harmony Biosciences reported Q3 2026 revenue of $268.92M, up 12.3% YoY, but net income fell 5.2% to $48.2M and EPS declined 6.9% to $0.81. WAKIX revenue grew 12.3% in the quarter, driven by higher shipments and a price increase. The FDA accepted the Pitolisant GR NDA for review, with a target PDUFA date of April 1, 2027. Phase 3 trials for EPX-100 and Pitolisant HD are ongoing, with results expected in 2027. The company also began a Phase 1b study of BP-205.

tradingview.com1 min
NOV 4
$HRMYMedAI 8/10

Harmony Biosciences Reports Q3 Financial Results

Harmony Biosciences Holdings, Inc. (HRMY) filed an SEC Form 8-K — Results of Operations and Financial Condition. ‌ Exhibit 99.1 Harmony Biosciences Reports Q3 Financial Results On Track to Achieve More Than $1 Billion WAKIX Net Revenue and Announces Strong Multiple-Ascending Dose Data for Its Orexin Agonist BP-205, Supporting Potential Best-in-Class Profile ​ WAKIX ® Net Revenue in Q3 of $2

SEC EDGAR 8-K2 min